WG
KALV

Winton Group’s KalVista Pharmaceuticals KALV Stock Holding History

Winton Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,427
Closed -$194K – 1418
2020
Q3 		$194K Buy
15,427
+521
+3% +$6.51K 0.01% 1352
2020
Q2 		$180K Buy
14,906
+302
+2% +$3.21K ﹤0.01% 1367
2020
Q1 		$112K Sell
14,604
-19,636
-57% -$265K ﹤0.01% 1319
2019
Q4 		$610K Buy
+34,240
New +$447K 0.01% 1190

Other funds holding KALV

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Winton Group's KALV Position: Q4 2020 in Review

Winton Group sold out of KalVista Pharmaceuticals (KALV) in Q4 2020, closing a stake of 15,427 shares — an estimated $194K sold.

Winton Group first reported a position in KALV in Q4 2019 and held it in 4 quarters. The position peaked at $610K in Q4 2019. 82 funds tracked by Wall St. Rank hold KALV as of Q4 2020.

  • Winton Group reported no remaining KalVista Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 15,427 KalVista Pharmaceuticals shares in Q4 2020, an estimated $194K.
  • Winton Group first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Winton Group's KalVista Pharmaceuticals position peaked at $610K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.